Clinical Research in India – Regulatory Environment

Clinical Trials, Emerging Market, Life Sciences, Pharmaceutical,
  • Wednesday, May 09, 2012 | 10am BST (UK) / 11am CEST (EU-Central) / 5am EDT (NA)
  • 0 min

Recording Not Available for this Webinar

India has become an attractive destination for clinical trials, combining many of the elements western sponsors require including: a vibrant urban health care environment, English as the language of clinical trials, first rate medical credentials of CRAs and Project Managers, and an advanced clinical trial infrastructure.

Indeed, Indian based regulatory bodies cooperate fully with international agencies, to ensure regulatory standards meet the requirements of USA FDA and ICH GCP guidelines. As a result of the Indian government’s initiatives, the FDA established it’s second ‘ex-USA’ office in India in 2009.

The country’s regulatory authorities are committed to progressive review and approval of foreign clinical research requests, willing to learn from and improve upon methods when challenges are faced. They continue preparing in anticipation of increasing growth from around the world to conduct their clinical trial studies in India.

Still, with growth and change, as within any other Government regulatory body, Sponsor updates about time to approval, involvement of agencies in the approval process, and processing of import/export licenses, retain a high priority, with Sponsors.

This program will analyze the basis of India’s Regulatory environment, the regulations [both current and future] of clinical trials in India, and the challenges faced in the present scenario.

Join Max Neeman’s Regulatory experts as they present India’s Regulatory
scenario and continuous growth to meet challenges as they arise.

     Key Takeaway Points:
– Gain a comprehensive overview of the regulatory requirements in India
– Develop effective processes for obtaining clinical trials authorization
– Clarify the requirements for running clinical trials in special population
– Marketing opportunities in India and the regulatory requirements



Renu Razdan, PhD, Chief Operating Officer, Max Neeman International

Dr. Renu Razdan heads the business development team in India and looks after business in Europe and the southeast Asian regions. Dr. Renu brings in 10 years of experience. Prior to joining Max Neeman International, she worked for 6 years with Ranbaxy Laboratories Ltd.

Dr. Renu has pursued an ICRETT Fellowship of UICC Geneva, at International Agency for Research on Cancer Lyon (France) and a G.S.F. Fellowship at German Cancer Research Centre (DKFZ), Heidelberg.

Message Presenter

Vandana Pandey, Manager Regulatory Affairs, Max Neeman International

Ms. Vandana Pandey heads the Regulatory Department at Max Neeman International in India. She has seven years of experience in working in Clinical Research and Life Sciences companies.

She has been associated with Max Neeman International for last five years and is responsible for all the Regulatory related activities. Prior to joining Max Neeman International, she worked for two years with CD Pharma India Pvt. Ltd.

Ms. Vandana Pandey holds a Masters Degree in Microbiology from University of Delhi.

Message Presenter

Who Should Attend?

Industry decision-makers involved in identifying strategic venues for clinical research and looking to understand better the potential of clinical research in India and their Regulatory environment.

Xtalks Partner

Max Neeman

Max Neeman International is a leading India-centric Contract Research Organization and the wholly-owned clinical research subsidiary of Max India Limited, reputed business group with interests in healthcare, clinical research and life insurance. For over a decade, Max Neeman has offered customized services to global pharmaceutical, biotech and device companies in the conduct of clinical and device trials as well as data management. Operational since 2001, Max Neeman is an ISO certified CRO for Site Management, Monitoring, Data Management, Information Security Management Systems and Clinical Investigation of Medical Devices with 6 regional offices, 175 sites across 31 cities, headquarters in New Delhi and USA office based in Cary, North Carolina.

Max Neeman has been awarded 265 trials and 85% of >300 employees are M.D.’s trained in ICH GCP guidelines.

Services include:

  • Project Management
  • Regulatory Submission
  • Site Monitoring
  • Clinical Data Management
  • Biometrics and Report Writing
  • Site Management
  • Device Importation, Warehousing & Distribution

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account